Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health and Novaliq announced successful results from the first Phase 3 trial (GOBI) of NOV03 for treating dry eye disease associated with meibomian gland dysfunction. The trial met both co-primary endpoints, achieving statistical significance in corneal staining and dryness scores at day 15, with continued positive results through day 57. Over 16 million U.S. adults suffer from dry eye disease, making this drug significant. Further studies (MOJAVE and KALAHARI) will assess safety and efficacy, potentially leading to FDA filing in 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the release of its first-quarter 2021 financial results on May 4, 2021, at 8:00 a.m. EDT. A conference call will be held to discuss these results along with a business update. Interested participants can access the call via a provided webcast link. Bausch Health focuses on developing health care products across various therapeutic areas, including eye health and gastroenterology. More information is available on their website.
Bausch Health Companies Inc. launched ENVIVE™, a daily probiotic supplement, on April 8, 2021, targeting occasional gastrointestinal symptoms like diarrhea and bloating. The product aims to strengthen the gut barrier and has shown effectiveness in clinical trials, with 85% of participants reporting improved GI well-being. Priced at $16.99, ENVIVE™ is available at major retailers such as Target and CVS. This launch reflects Bausch Health's commitment to addressing consumer health needs, particularly as 61% of Americans experience GI issues.
Bausch + Lomb announced the FDA approval of ClearVisc™, a dispersive ophthalmic viscosurgical device (OVD) designed for ophthalmic surgeries, particularly cataract procedures. This innovative OVD provides enhanced corneal protection and visibility, utilizing Sorbitol for superior free radical protection. In clinical trials with 372 subjects, ClearVisc™ demonstrated non-inferior safety and efficacy compared to VISCOAT®, with excellent postoperative outcomes. This approval reflects Bausch + Lomb's commitment to advancing eye health technology and meeting surgical needs.
Bausch Health Companies announced a $100 million debt reduction plan through the redemption of its 7.00% Senior Secured Notes due 2024, scheduled for May 7, 2021. This action follows a previous redemption of $200 million in March 2021. The company aims to utilize cash generated from operations for this redemption, signifying improved liquidity. Bausch Health, focused on health care products across various therapeutic areas, continues to prioritize financial stability amid ongoing uncertainties due to the COVID-19 pandemic.
Bausch Health Companies (NYSE/TSX: BHC) announced a definitive agreement to sell its equity interests in Amoun Pharmaceutical Company for approximately U.S. $740 million. The sale aims to reduce Bausch Health's debt and is expected to close in the first half of 2021, pending regulatory approvals. Amoun is a leading pharmaceutical firm in Egypt known for its branded generics. The transaction includes adjustments for cash generated by Amoun from January 1, 2021, until closing, which will not reflect on Bausch Health's consolidated results.
Bausch Health Companies (NYSE/TSX: BHC) announced the launch of GastroHub for Advanced Practice Providers, a website offering free educational resources for nurse practitioners and physician assistants treating IBS-D and hepatic encephalopathy. Developed with input from healthcare professionals, it includes videos, podcasts, and discussion guides. This initiative follows two other educational platforms launched by Salix Pharmaceuticals within the past year, aiming to enhance patient care in gastrointestinal health.
Bausch Health Companies Inc. (NYSE: BHC) announced a leadership change with Sam Eldessouky succeeding Paul S. Herendeen as CFO, effective June 1, 2021. Herendeen will transition to an advisory role while remaining an executive vice president. Eldessouky, who has been with the company since 2016, brings significant experience, particularly in financial strategy and executing corporate spinoffs. The company also provided an update on its planned spinoff of Bausch + Lomb, indicating ongoing progress in that effort.
Bausch Health Companies Inc. (NYSE/TSX: BHC) presented an update at the Barclays Global Healthcare Conference on March 9, 2021. CEO Joseph C. Papa, along with other executives, detailed the company's current pipeline, particularly focusing on Salix and its rifaximin clinical development efforts. The presentation is accessible via the Investor Relations page on the Bausch Health website, allowing stakeholders to follow developments in this therapeutic area. Forward-looking statements indicate potential risks related to COVID-19 and project timelines, which might impact future performance.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched the Clear + Brilliant® Touch laser, enhancing treatment protocols for patients of all ages and skin types. This next-generation system features dual wavelengths, allowing aesthetic providers to offer enhanced treatments in a single session. Notable features include a user-friendly touchscreen and smart charting assistant. As a pioneer in medical aesthetics, Solta Medical continues to advance technologies aimed at improving patient outcomes. The Clear + Brilliant laser has conducted over 2.5 million procedures since its inception.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
